HAYWARD, Calif., Sept. 6 /PRNewswire/ -- Acologix, Inc., a privately-held biopharmaceutical company, announced today that it has licensed technology from the University of Maryland, Baltimore, for the potential treatment of interstitial cystitis (IC). A chronic bladder condition characterized by serious pain and increased frequency of urination, interstitial cystitis affects an estimated 700,000 Americans, of whom approximately 90 percent are women. To date, there are no satisfactory treatments for this condition.
